A Novel Method for Making 212 Pb-labeled Monoclonal Antibodies Using a Novel 224 Ra-based Generator Solution

Oncoinvent researchers collaborate to develop a system to generate alpha-particle releasing radioimmunoconjugates that may be simpler and less time-consuming compared with current established methods used in clinical trials.

Alpha-particles have the potential to kill tumor cells very effectively and selectively. The radioisotope 212Pb, which causes the release of alpha-particle, has a half-life of 10.6 h which imposes time constraints to its practical application as a radioimmunoconjugate for cancer therapy.  The focus of the published research was to determine whether a rapid, efficient, and reliable production and purification procedure for generating a 212Pb based radioimmunoconjugate could be developed.

Key Conclusion:

The current work demonstrates the feasibility of using a 224Ra solution as a shippable generator solution for producing 212Pb-based radioimmunoconjugates, which may be easier to execute and less time-consuming for the end user in comparison with existing ion exchange based methods.

A free access copy of the article can be obtained through the online version of the journal: http://www.sciencedirect.com/science/journal/09698051